Neurocrine Biosciences, Inc. (NBIX) Director Gary A. Lyons Sells 5,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Gary A. Lyons sold 5,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $84.67, for a total transaction of $423,350.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $84.58 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 10.20 and a quick ratio of 10.20. Neurocrine Biosciences, Inc. has a 12-month low of $39.21 and a 12-month high of $91.82. The stock has a market cap of $7,480.00, a P/E ratio of -51.89 and a beta of 0.26.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The firm had revenue of $94.52 million for the quarter, compared to analysts’ expectations of $94.00 million. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. research analysts forecast that Neurocrine Biosciences, Inc. will post -0.11 earnings per share for the current year.

Several institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its position in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after buying an additional 193 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after buying an additional 810 shares during the last quarter. Amalgamated Bank grew its position in shares of Neurocrine Biosciences by 5.7% in the 4th quarter. Amalgamated Bank now owns 17,484 shares of the company’s stock worth $1,357,000 after buying an additional 947 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Neurocrine Biosciences by 25.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the company’s stock worth $458,000 after buying an additional 1,200 shares during the last quarter. Finally, Grandfield & Dodd LLC grew its position in shares of Neurocrine Biosciences by 24.1% in the 3rd quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock worth $466,000 after buying an additional 1,480 shares during the last quarter.

NBIX has been the topic of a number of research reports. Jefferies Group raised their target price on shares of Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets raised their target price on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer set a $85.00 target price on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and set a $86.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and set a $83.00 target price (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $89.71.

COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences, Inc. (NBIX) Director Gary A. Lyons Sells 5,000 Shares” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/02/21/neurocrine-biosciences-inc-nbix-director-gary-a-lyons-sells-5000-shares.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply